Transparency Market Research U.S. Vaccine Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
Published Date 27-Jan-2015
83 Page Report
Buy Now
Request Sample
Press Release
Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com
U.S. Vaccine Market
REPORT DESCRIPTION
U.S. Vaccine Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 A vaccine is a biological preparation of killed forms of microbes, living attenuated organisms, living fully virulent organisms, a microbe’s toxins or one of its surface proteins. Vaccines play a key role in improving immunity against particular diseases. Therefore, vaccination is promoted as a vital public health intervention throughout the globe. According to the World Health Organization (WHO), vaccination has reduced the burden of infectious disease globally to a great extent. According to a study conducted by Zhou et al, vaccination prevented 42,000 early deaths and approximately 20 million cases of diseases in children born in the U.S. in 2009, resulting in saving USD 13.5 billion in direct medical and non-medical costs and USD 68.8 billion in total societal costs. Browse U.S. Vaccine Market Report with Full TOC at http://www.transparencymarketresearch.com/us-vaccine-market.html This report on the U.S. vaccine market offers an insightful and in-depth assessment of the current as well as future market potential of human as well as animal vaccine markets. The human vaccine market is further segmented into pediatric and adult vaccine markets, based on vaccine type. On the basis of different antigens, the U.S. human vaccine market has been categorized into hepatitis, influenza, meningococcal, pneumococcal, human papillomavirus (HPV), combination vaccines and others. The U.S. animal vaccine market is broadly segmented as companion animal and livestock vaccine markets. The U.S. companion animal vaccine market segment has been further categorized into canine and feline, while the livestock vaccine market has been divided into porcine, bovine, ovine, poultry and equine markets. Each of these segments and sub-segments has been extensively analyzed in the report, considering factors such as market trends, recent developments, future outlook and opportunities. The report provides market revenue size in terms of USD million for each segment and sub-segment for the period 2012 to 2020. In addition, the compounded annual growth rate (CAGR) of the overall U.S. vaccine market and various segments and sub-segments has also been provided in the report for the forecast period 2014 to 2020, considering 2012 and 2013 as the base years. This report includes an elaborate executive summary, which covers a market snapshot representing key findings from the study on the U.S. vaccine market. The market overview section of the report on the U.S. vaccine market comprises qualitative analysis of the overall market considering factors determining market dynamics such as growth drivers, restraints and opportunities. The market overview chapter also includes a section describing the vaccine approval and regulatory pathway in the U.S. The competitive landscape section has been provided for both human and animal vaccine markets. This section presents the market revenue share of key players in terms of percentage for the year 2013. The market share analysis of key players involved the study of company product portfolio and sales revenue along with market developments such as new product launch and regulatory approvals. This study on the U.S. vaccine market suggests a list of recommendations for new companies willing to enter the market and for existing companies to accentuate revenue shares, which is likely to help in the
Transparency Market Research
2
U.S. Vaccine Market
decision-making process. The report concludes with the profiles of major players in the U.S. vaccine market such as GlaxoSmithKline plc, Merck & Co., Inc., Novartis International AG, Pfizer, Ltd., Sanofi, Boehringer Ingelheim and Zoetis, Inc. Each company profile in the report contains information such as company overview, financial overview, product portfolio, business strategies and recent developments. The company overview section comprises basic information about the company such as major business areas, company’s brief history and its establishment year, number of employees and geographical presence. In the financial overview section, information such as selling and general administrative expenses, R&D expenses and annual revenue for the last three consecutive years (2011, 2012 and 2013) has been provided. The business strategies section mentions key strategies adopted by the company in the past to strengthen its position in the vaccine market. The recent development section gives information about the recent happening in the company related with the vaccine market.
The U.S. vaccine market is segmented as follows:
U.S. Human Vaccine Market, by Type
•
Pediatric
•
Adult
U.S. Human Vaccine Market, by Antigen
•
Hepatitis (A & B)
•
Influenza
•
Meningococcal
•
Pneumococcal
•
Human Papillomavirus (HPV)
•
Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV)
•
Others
Transparency Market Research
3
U.S. Vaccine Market
U.S. Animal Vaccine Market, by Animal Type
Companion Animal Vaccine Market
•
Canine
•
Feline
Livestock Vaccine Market •
Porcine
•
Bovine
•
Ovine
•
Poultry
•
Equine
Browse U.S. Vaccine Market Report with Full TOC at http://www.transparencymarketresearch.com/us-vaccine-market.html
TABLE OF CONTENT
Chapter 1 Preface 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.3.1 Assumptions 1.3.2 Sources 1.3.2.1 Secondary Research
Transparency Market Research
4
U.S. Vaccine Market
1.3.2.2 Primary Research 1.3.3 Models
Chapter 2 Executive Summary 2.1 Market Snapshot: U.S. Vaccine Market (2013 & 2020) 2.2 U.S. Human Vaccine Market, by Antigen, 2013 (USD Million)
Chapter 3 U.S. Vaccine Market Overview 3.1 Introduction 3.2 Vaccine Approval Regulatory Pathway 3.2.1 Major Steps: Vaccine Development and Commercialization 3.3 Drivers 3.3.1 Growing incidence of zoonotic diseases drives increased animal vaccination 3.3.2 Increasing consumption of chicken to augment the demand of poultry vaccines in the U.S. 3.3.3 Extremely low risk of serious and fatal side effects associated with vaccines is a strong driver in the adoption of vaccines 3.3.4 Education and awareness through various governmental and non-profit organizations 3.4 Restraints 3.4.1 Strict regulatory pathway and high cost associated with new vaccine discovery and development 3.4.2 High cost associated with vaccine transportation, storage and handling 3.5 Opportunities 3.5.1 DNA vaccines hold immense potential for a number of human and animal diseases
Transparency Market Research
5
U.S. Vaccine Market
3.5.2 The U.S. offers immense potential for adult vaccines market 3.6 Competitive Landscape 3.6.1 U.S. Human Vaccine Market Share Analysis, by Key Players, 2013 (Value %) 3.6.2 U.S. Animal Vaccine Market Share Analysis, by Key Players, 2013 (Value %)
Chapter 4 U.S. Human Vaccine Market Revenue 4.1 Overview 4.1.1 U.S. Human Vaccine Market Revenue, by Type, 2012 – 2020 (USD Million) 4.1.2 U.S. Human Vaccine Market Revenue, by Antigen, 2012 – 2020 (USD Million) 4.1.3 Comparative Analysis: U.S. Human Vaccine Market Revenue, by Antigen, 2013 & 2020 (Value %) 4.1.4 Hepatitis 4.1.4.1 U.S. Hepatitis Vaccine Market Revenue, 2012 – 2020 (USD Million) 4.1.5 Influenza 4.1.5.1 U.S. Influenza Vaccine Market Revenue, 2012 – 2020 (USD Million) 4.1.6 Meningococcal 4.1.6.1 U.S. Meningococcal Vaccine Market Revenue, 2012 – 2020 (USD Million) 4.1.7 Pneumococcal 4.1.7.1 U.S. Pneumococcal Vaccine Market Revenue, 2012 – 2020 (USD Million) 4.1.8 Human Papillomavirus (HPV) 4.1.8.1 U.S. Human Papillomavirus Vaccine Market Revenue, 2012 – 2020 (USD Million) 4.2 Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV) 4.2.1 U.S. Combination Vaccine Market Revenue, 2012 – 2020 (USD Million)
Transparency Market Research
6
U.S. Vaccine Market
4.2.2 Others 4.2.2.1 U.S. Other Vaccine Market Revenue, 2012 – 2020 (USD Million)
Chapter 5 U.S. Animal Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.1 Overview 5.1.1 U.S. Animal Vaccine Market Revenue, by Animal Type, 2012 – 2020 (USD Million) 5.1.2 Comparative Analysis: U.S. Animal Vaccine Market Revenue, by Animal Type, 2013 & 2020 (Value %) 5.2 Companion Animal Vaccines 5.2.1 U.S. Companion Animal Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million) 5.2.2 Canine Vaccines 5.2.2.1 U.S. Canine Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.2.3 Feline Vaccines 5.2.3.1 U.S. Feline Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.3 Livestock Vaccines 5.3.1 U.S. Livestock Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million) 5.3.2 Porcine Vaccines 5.3.2.1 U.S. Porcine Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.3.3 Bovine Vaccines 5.3.3.1 U.S. Bovine Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.3.4 Ovine Vaccines 5.3.4.1 U.S. Ovine Vaccine Market Revenue, 2012 – 2020 (USD Million)
Transparency Market Research
7
U.S. Vaccine Market
5.3.5 Poultry Vaccines 5.3.5.1 U.S. Poultry Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.3.6 Equine Vaccines 5.3.6.1 U.S. Equine Vaccine Market Revenue, 2012 – 2020 (USD Million)
Chapter 6 Recommendations 6.1 Focus on cost-effective vaccine manufacturing 6.2 Focus on developing technologically advanced vaccines such as DNA vaccines
Chapter 7 Company Profiles 7.1 Boehringer Ingelheim 7.1.1 Company Overview 7.1.2 Financial Overview 7.1.3 Product Portfolio 7.1.4 Business Strategies 7.1.5 Recent Developments 7.2 GlaxoSmithKline plc 7.2.1 Company Overview 7.2.2 Financial Overview 7.2.3 Product Portfolio 7.2.4 Business Strategies 7.2.5 Recent Developments
Transparency Market Research
8
U.S. Vaccine Market
7.3 Merck & Co., Inc. 7.3.1 Company Overview 7.3.2 Financial Overview 7.3.3 Product Portfolio 7.3.4 Business Strategies 7.3.5 Recent Developments 7.4 Novartis International AG 7.4.1 Company Overview 7.4.2 Financial Overview 7.4.3 Product Portfolio 7.4.4 Business Strategies 7.4.5 Recent Developments 7.5 Pfizer, Inc. 7.5.1 Company Overview 7.5.2 Financial Overview 7.5.3 Product Portfolio 7.5.4 Business Strategies 7.5.5 Recent Developments 7.6 Sanofi SA 7.6.1 Company Overview 7.6.2 Financial Overview 7.6.3 Product Portfolio
Transparency Market Research
9
U.S. Vaccine Market
7.6.4 Business Strategies 7.6.5 Recent Developments 7.7 Zoetis, Inc. 7.7.1 Company Overview 7.7.2 Financial Overview 7.7.3 Product Portfolio 7.7.4 Business Strategies 7.7.5 Recent Developments Browse U.S. Vaccine Market Report with Full TOC at http://www.transparencymarketresearch.com/us-vaccine-market.html
About Us
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207
Transparency Market Research
10
U.S. Vaccine Market
United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/
Transparency Market Research
11